Chimeric antigen receptor T cells or CAR-T cells -engineered cytotoxic T cells that express synthetic CAR receptors -has been of continued interest to the scientific community since their onset. Our trend landscape analysis (Fig. ) indicates continued growth of publications for CAR therapies (CAR-T, CD19 CAR, CAR-NK). Chimeric receptors combine antigen recognition and T cell binding capability in a single receptor. The receptor portion of CARs consists of four prominent segments -an extracellular domain derived from the single chain variable fragment (sc-Fv) of the antibody, which is responsible for tumor antigen recognition, a hinge region that connects the sc-Fv fragment to the transmembrane (TM) domain, and the intracellular signaling domain. The hinge region and the TM domain anchor CARs to the cell membrane and help in the downstream signaling cascade for T cell activation. CAR-T cells are created by harvesting T cells from the patient's blood, genetically modifying them to target cancer cells specifically, and multiplying their numbers. These modified cells are then reintroduced into the patient's bloodstream to attack the cancer cells. CAR-T cells have shown promising results in treating hematological cancers, such as acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and multiple myeloma. Kymriah (tisagenlecleucel) was the first US FDA-approved CAR-T cell therapy developed by Novartis. This CD19-directed therapy was approved in 2017 for the treatment of B-cell acute lymphoblastic leukemia (ALL). To date, five more CAR-T cell therapies have been approved by the US FDA (Table ). While CAR-T cell therapy has shown remarkable success in treating hematological cancers, their use in solid tumors such as gastric, pancreatic, and lung cancer is still in exploratory stages. The challenge of using CAR-T immunotherapy in solid tumors arises from a lack of suitable CAR-T antigens and the tumors' immune-suppressive and complex microenvironment which poses difficulties in the trafficking of CAR-T cells. Current research is focused on improving infiltration of solid tumors by administering CAR-T-based therapy directly to the tumor site rather than through the bloodstream. To date, >1,100 trials for CAR-T therapies are ongoing, of which ~150 are directed towards solid tumors. In recent years, CAR-NK and CAR-M therapies are being developed as alternate/synergistic therapies for solid tumors. Despite its effectiveness, CAR-T therapies have disadvantages such as heightened immune reactions including cytokine release syndrome, CAR T cell-related encephalopathy syndrome, off-tumor toxicities, and immune effector cell-associated neurotoxicity syndrome. Another major concern is the high cost of therapy. However, various efforts are being made to counter the drawbacks of CAR-T therapy such as optimizing autologous CAR-Ts for liquid tumors, 104 expanding CAR administering facilities and developing next-generation CAR T-cell therapies.